Anavex Life Sciences Corp.

10.17-0.2800-2.68%Vol 1.22M1Y Perf -58.10%
Jun 24th, 2022 16:00 DELAYED
BID9.78 ASK10.20
Open10.56 Previous Close10.45
Pre-Market- After-Market10.17
 - -  - -%
Target Price
33.00 
Analyst Rating
Strong Buy 1.00
Potential %
224.48 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
12.47 
Earnings Rating
Strong Buy
Market Cap787.24M 
Earnings Date
11th Aug 2022
Alpha0.02 Standard Deviation0.24
Beta0.92 

Today's Price Range

9.7810.66

52W Range

7.1331.50

5 Year PE Ratio Range

-8.80-10.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
20.07%
1 Month
11.76%
3 Months
-18.51%
6 Months
-47.85%
1 Year
-58.10%
3 Years
208.18%
5 Years
78.42%
10 Years
142.14%

TickerPriceChg.Chg.%
AVXL10.17-0.2800-2.68
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.16-0.1412.50
Q01 2022-0.16-0.1412.50
Q04 2021-0.13-0.15-15.38
Q03 2021-0.13-0.14-7.69
Q02 2021-0.12-0.120.00
Q01 2021-0.11-0.12-9.09
Q04 2020-0.13-0.1023.08
Q03 2020-0.14-0.1121.43
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1516.67Positive
9/2022 QR-0.1615.79Positive
9/2022 FY-0.6034.07Positive
9/2023 FY-0.26-13.04Negative
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.15
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.22M
Shares Outstanding77.41K
Shares Float75.25M
Trades Count9.59K
Dollar Volume12.41M
Avg. Volume1.19M
Avg. Weekly Volume1.72M
Avg. Monthly Volume992.78K
Avg. Quarterly Volume865.93K

Anavex Life Sciences Corp. (NASDAQ: AVXL) stock closed at 10.17 per share at the end of the most recent trading day (a -2.68% change compared to the prior day closing price) with a volume of 1.22M shares and market capitalization of 787.24M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Anavex Life Sciences Corp. CEO is Christopher U. Missling.

The one-year performance of Anavex Life Sciences Corp. stock is -58.1%, while year-to-date (YTD) performance is -41.35%. AVXL stock has a five-year performance of 78.42%. Its 52-week range is between 7.13 and 31.5, which gives AVXL stock a 52-week price range ratio of 12.47%

Anavex Life Sciences Corp. currently has a PE ratio of -14.90, a price-to-book (PB) ratio of 4.31, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.45%, a ROC of -37.92% and a ROE of -37.91%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Anavex Life Sciences Corp., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Anavex Life Sciences Corp.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Anavex Life Sciences Corp. is Strong Buy (1), with a target price of $33, which is +224.48% compared to the current price. The earnings rating for Anavex Life Sciences Corp. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anavex Life Sciences Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anavex Life Sciences Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 41.60, ATR14 : 0.76, CCI20 : 164.33, Chaikin Money Flow : 0.09, MACD : 0.12, Money Flow Index : 60.69, ROC : 14.14, RSI : 60.31, STOCH (14,3) : 85.15, STOCH RSI : 0.87, UO : 63.58, Williams %R : -14.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anavex Life Sciences Corp. in the last 12-months were: Christopher U. Missling (Option Excercise at a value of $68 138), Christopher U. Missling (Sold 51 620 shares of value $1 342 120 ), Sandra Boenisch (Option Excercise at a value of $699 163), Sandra Boenisch (Sold 166 696 shares of value $4 422 445 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.

CEO: Christopher U. Missling

Telephone: +1 844 689-3939

Address: 51 West 52nd Street, New York 10019, NY, US

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

56%44%

Bearish Bullish

59%41%

TipRanks News for AVXL

News

Stocktwits